



**Listing of Claims:**

**Claim 1** (cancelled)

**Claim 1** <sup>1</sup>/<sub>5</sub> (new) A compound of the formula



wherein  $\phi$  is phenylene with 1 to 2 substituents selected from the group consisting of hydrogen, halogen, -OH, and alkyl or alkoxy of 1 to 6 carbon atoms, A is




, W is a bond,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  are individually selected from the group consisting of hydrogen, halogen, -OH, -CN, -NO<sub>2</sub>, -NR<sub>6</sub>R<sub>7</sub> and alkyl and alkoxy of 1 to 6 carbon atoms,  $R_6$  and  $R_7$  are individually selected from the group consisting of hydrogen, -OH, -COR<sub>8</sub> and alkyl or alkoxy of 1 to 6 carbon atoms,  $R_8$  is selected from the group consisting of hydrogen, -OH, -NR<sub>9</sub>R<sub>10</sub> and alkyl or alkoxy of 1 to 6 carbon atoms,  $R_9$  and  $R_{10}$  are individually selected from the group consisting of hydrogen, -OH and alkyl of 1 to 6 carbon atoms,  $R_{11}$  is selected from the group consisting of hydrogen,

-OH, -COR<sub>12</sub> and alkyl or alkoxy of 1 to 6 carbon atoms, R<sub>12</sub> is selected from the group consisting of hydrogen, -OH and alkyl of 1 to 6 carbon atoms, B is selected from the group consisting of -CH<sub>2</sub>-NO<sub>2</sub>, alkyl of 1 to 6 carbon atoms, -NR<sub>13</sub>R<sub>14</sub> and unsubstituted and substituted carbocyclic aryl and heterocyclic aryl of 5 to 6 ring members containing 1 to 4 heteroatoms containing 1 to 4 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, the aryl substituents being selected from the group consisting of alkyl, alkenyl and alkoxy of up to 6 carbon atoms, R<sub>13</sub> and R<sub>14</sub> are individually selected from the group consisting of hydrogen, -CN, -NO<sub>2</sub> and alkyl of 1 to 6 carbon atoms or together with the nitrogen form a non-aromatic heterocycle of 5 to 6 ring members selected from the group consisting of -CH<sub>2</sub>-, -NH-, -O- and S-, X is selected from the group consisting of a bond, -(CH<sub>2</sub>)<sub>k</sub>-NR<sub>16</sub>-, -O-, -S-, -CO-, -NR<sub>16</sub>-CO-, -CO-NR<sub>16</sub>-, -O-CO-, -CO-O-, -NR<sub>16</sub>-CO-O- and -NR<sub>16</sub>-CO-NR<sub>17</sub>-, k is 0 or 1, Y represents a bond or a radical chosen from the -(CH<sub>2</sub>)<sub>m</sub>-, (CH<sub>2</sub>)<sub>m</sub>-O-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-S-(CH<sub>2</sub>)<sub>n</sub>-, -(CH)<sub>m</sub>-NR<sub>18</sub>(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-NR<sub>18</sub>-CO-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-CO-NR<sub>18</sub>-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-Q-(CH<sub>2</sub>)<sub>n</sub>-radicals, Q is selected from the group consisting of piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-oxypiperidine and 4-aminopiperidine, m and n are individually integers from 0 to 6, R<sub>16</sub>, R<sub>17</sub> and R<sub>18</sub> are individually a hydrogen atom or alkyl of 1 to 6 carbon atoms and its pharmaceutically acceptable salt with acids or bases.

<sup>2</sup>  
Claim ~~16~~ (new)


The compound of claim ~~15~~ wherein A is



$R_1, R_2, R_3, R_4, R_5$  are individually selected from the group consisting of hydrogen, halogen, -OH and alkyl and alkoxy of 1 to 6 carbon atoms,  $R_{11}$  is hydrogen atom or alkyl of 1 to 6 carbon atoms, B is a substituted or unsubstituted carbocyclic aryl or heterocyclic aryl of 5 to 6 ring members containing 1 to 4 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, the aryl substituents being selected from the group consisting of alkyl, alkenyl and alkoxy of up to 6 carbon atoms, W is a bond, X is selected from the group consisting of a bond,  $-(CH_2)_k-NR_{16}-$ ,  $-O-$ ,  $-S-$ ,  $-CO-$ ,  $-NR_{16}-CO-$ ,  $-CO-NR_{16}-$ ,  $-O-CO-$ ,  $-CO-O-$ ,  $-NR_{16}-CO-O-$  and  $-NR_{16}-CO-NR_{17}-$ , k is 0 or 1, Y is selected from the group consisting of a bond,  $-(CH_2)_m-$ ,  $-(CH_2)_m-O-(CH_2)_n-$ ,  $-(CH_2)_m-S-(CH_2)_n-$ ,  $-(CH_2)_m-NR_{18}-(CH_2)_n-$ ,  $-(CH_2)_m-NR_{18}-CO-(CH_2)_n-$ ,  $-(CH_2)_m-CO-NR_{18}-(CH_2)_n-$  and  $-(CH_2)_m-Q-(CH_2)_n-$ , Q is selected from the group consisting of piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-oxypiperazine or 4-aminopiperidine and m and n are integers from 0 to 6.


3  
**Claim 17.** (new) The compound of claim 15 wherein B is selected from the group consisting of thiophene, furan, pyrrole and thiazole.

4  
**Claim 18.** (new) The compound of claim 15 wherein A is



$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are individually selected from hydrogen, -OH and alkyl and alkoxy of 1 to 6 carbon atoms,  $R_{11}$  is hydrogen or methyl, B is selected from the group consisting of unsubstituted or substituted phenyl, thiophene, furan, pyrrole and thiazole, the substituents being at least one member of the group consisting of alkyl, alkenyl and alkoxy of up to 6 carbon atoms, W is a bond, X is selected from the group consisting of a bond,  $-(CH_2)_k-NR_{16}-$ ,  $-O-$ ,  $-S-$ ,  $-CO-$ ,  $-NR_{16}-CO-$ ,  $-CO-NR_{16}-$ ,  $-O-CO-$ ,  $-CO-O-$ ,  $-NR_{16}-CO-O-$  and  $-NR_{16}-CO-NR_{17}-$ , k is 0 or 1, Y is selected from the group consisting of a bond,  $-(CH_2)_m-$ ,  $-(CH_2)_m-O-(CH_2)_n-$ ,  $-(CH_2)_m-S-(CH_2)_n-$ ,  $-(CH_2)_m-NR_{18}-(CH_2)_n-$ ,  $-(CH_2)_m-NR_{18}-CO-(CH_2)_n-$ ,  $-(CH_2)_m-CO-NR_{18}-(CH_2)_n-$  and  $-(CH_2)_m-Q-(CH_2)_n-$ , Q is selected from the group consisting of piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-oxypiperidine or 4-aminopiperidine and m and n are integers from 0 to 6.

~~Claim 19~~ (new) The compound of claim ~~15~~ wherein A is



$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  are individually hydrogen or methyl,  $R_{11}$  is hydrogen or methyl, B is thiophene, W is a bond, X does not exist or is selected from the group consisting of  $-(CH_2)_k-NR_{16}-$ ,  $-O-$ ,  $-S-$ ,  $-CO-$ ,  $-NR_{16}-CO-$ ,  $-CO-NR_{16}-$ ,  $-O-CO-$ ,  $-CO-O-$ ,  $-NR_{16}-CO-O-$  and  $-NR_{16}-CO-NR_{17}-$ , k is 0 or 1, Y is selected from the group consisting of  $-(CH_2)_m-$ ,

$-(CH_2)_m-O-(CH_2)_n-$ ,  $-(CH_2)_m-S-(CH_2)_n-$ ,  $-(CH_2)_m-NR_{18}-(CH_2)_n-$ ,  $-(CH_2)_m-NR_{18}-CO-$   
 $(CH_2)_n-$ ,  $-(CH_2)_m-CO-NR_{18}-(CH_2)_n-$  and  $-(CH_2)_m-Q-(CH_2)_n-$ , Q is piperazine, m and n are  
 integers from 0 and 6 and  $R_{16}$ ,  $R_{17}$  and  $R_{18}$  are hydrogen.

<sup>6</sup>  
~~Claim 20~~. (new) A compound of claim <sup>1</sup>~~15~~ which is 4-(4-([amino-(2-thienyl)methylidene]amino)phenyl)-N-(9H-carbazol-3-yl)butanamide or 2-(4-([amino(2-thienyl)methylidene]amino)phenyl)-N-[2-(9H-carbazol-4-yloxy)ethyl] acetamide and their pharmaceutically acceptable salts with acids and bases.

<sup>7</sup>  
~~Claim 21~~. (new) A compound of claim <sup>6</sup>~~20~~ in the form of its hydrochloride salt.

<sup>8</sup>  
~~Claim 22~~. (new) A composition for inhibiting NO synthase and/or lipidic peroxidation comprising an effective amount of a compound of claim <sup>1</sup>~~15~~ and an inert pharmaceutical carrier.

<sup>9</sup>  
~~Claim 23~~. (new) A method of inhibiting NO synthase in warm-blooded animals comprising administration to said patient of a NO synthase inhibitory amount of a compound of general formula (I) as defined in claim <sup>1</sup>~~15~~ or a pharmaceutically acceptable salt of said compound.


10  
Claim ~~24~~. (new) A method of inhibiting lipidic peroxidation in a patient in need thereof comprising administration to said patient of a lipidic peroxidation inhibitory amount of a compound of general formula (I) as defined in claim ~~15~~ or of a pharmaceutically acceptable salt of said compound.

11  
Claim ~~25~~. (new) A method of inhibiting both NO synthase and lipidic peroxidation in a patient in need thereof comprising administration to said patient of a compound of general formula (I) as defined in claim ~~15~~ or of a pharmaceutically acceptable salt of said compound, in an amount sufficient to inhibit both NO synthase and lipidic peroxidation.

## REMARKS

The amendment is submitted to insert reference to the present applications and their status, to add an Abstract and to present claims directed to subject matter non-elected therein.

Respectfully submitted,  
Muserlian, Lucas and Mercanti

By:   
Charles A. Muserlian, 19,683  
Attorney for Applicant(s)  
Tel. # (212) 661-8000

CAM:sd

Enclosures: Abstract of the Disclosure  
Return Receipt Postcard